Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors

GSKJ4, an H3K27me3 demethylase inhibitor, effectively suppresses the breast cancer stem cells

(2017) Ningning Yan et al.   EXPERIMENTAL CELL RESEARCH

Combination of palladium nanoparticles and tubastatin-A potentiates apoptosis in human breast cancer cells: a novel therapeutic approach for cancer

(2017) Yu-Guo Yuan et al.   International Journal of Nanomedicine

Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells

(2016) Zhao-Tong Wang et al.   CELLULAR SIGNALLING

Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology

(2016) Eunah Shin et al.   Journal of Translational Medicine

HDAC1 and HDAC2 integrate the expression of p53 mutants in pancreatic cancer

(2016) N Stojanovic et al.   ONCOGENE

Development and characterization of two human triple-negative breast cancer cell lines with highly tumorigenic and metastatic capabilities

(2016) Yanrong Su et al.   Cancer Medicine

Potentiation of growth inhibition and epigenetic modulation by combination of green tea polyphenol and 5-aza-2′-deoxycytidine in human breast cancer cells

(2015) Tulika Tyagi et al.   BREAST CANCER RESEARCH AND TREATMENT

Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts

(2015) Pragya Srivastava et al.   Epigenetics

Expression of epithelial-mesenchymal transition–related markers in triple-negative breast cancer: ZEB1 as a potential biomarker for poor clinical outcome

(2015) Min Hye Jang et al.   HUMAN PATHOLOGY

Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells

(2015) A. Schech et al.   MOLECULAR CANCER THERAPEUTICS

Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin

(2015) Yuting Kuang et al.   Molecular Oncology

DNMT1 is essential for mammary and cancer stem cell maintenance and tumorigenesis

(2015) Rajneesh Pathania et al.   Nature Communications

β-Catenin Is Required for the Tumorigenic Behavior of Triple-Negative Breast Cancer Cells

(2015) Jinhua Xu et al.   PLoS One

The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer

(2014) F. Fang et al.   CLINICAL CANCER RESEARCH

TGF-β induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells

(2014) Horacio Cardenas et al.   Epigenetics

SGI-110 and entinostat therapy reduces lung tumor burden and reprograms the epigenome

(2014) Carmen S. Tellez et al.   INTERNATIONAL JOURNAL OF CANCER

Immunomodulatory action of SGI-110, a hypomethylating agent, in acute myeloid leukemia cells and xenografts

(2014) Pragya Srivastava et al.   LEUKEMIA RESEARCH

Signaling mechanisms of the epithelial-mesenchymal transition

(2014) D. M. Gonzalez et al.   Science Signaling

Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin

(2013) Preeti Shah et al.   BREAST CANCER RESEARCH AND TREATMENT

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Multifaceted role of EZH2 in breast and prostate tumorigenesis

(2013) Gauri Deb et al.   Epigenetics

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

(2012) F. Andre et al.   ANNALS OF ONCOLOGY

Distincttumor protein p53mutants in breast cancer subgroups

(2012) Anne Dumay et al.   INTERNATIONAL JOURNAL OF CANCER

Histone Demethylase KDM6B Promotes Epithelial-Mesenchymal Transition

(2012) Sivakumar Ramadoss et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Global H3K27 trimethylation and EZH2 abundance in breast tumor subtypes

(2012) Karolina Holm et al.   Molecular Oncology

p53 mutations in cancer

(2012) Patricia A. J. Muller et al.   NATURE CELL BIOLOGY

Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis

(2012) P Dong et al.   ONCOGENE

Tumor Metastasis: Molecular Insights and Evolving Paradigms

(2011) Scott Valastyan et al.   CELL

Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer

(2011) Ali Aghdassi et al.   GUT

CD44+/CD24−/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome

(2011) Michael O. Idowu et al.   HUMAN PATHOLOGY

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2

(2011) Taewan Kim et al.   JOURNAL OF EXPERIMENTAL MEDICINE

p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs

(2011) Chun-Ju Chang et al.   NATURE CELL BIOLOGY

E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression

(2011) M-T Lau et al.   ONCOGENE

A Perspective on Cancer Cell Metastasis

(2011) C. L. Chaffer et al.   SCIENCE

The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis

(2010) Junjiang Fu et al.   CELL RESEARCH

MS-275 Sensitizes TRAIL-Resistant Breast Cancer Cells, Inhibits Angiogenesis and Metastasis, and Reverses Epithelial-Mesenchymal Transition In vivo

(2010) R. K. Srivastava et al.   MOLECULAR CANCER THERAPEUTICS

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

(2010) Fiona M. Blows et al.   PLOS MEDICINE

Triple-negative breast cancer--current status and future directions

(2009) O. Gluz et al.   ANNALS OF ONCOLOGY

Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines

(2009) Antoinette Hollestelle et al.   BREAST CANCER RESEARCH AND TREATMENT

HDAC Inhibitor SNDX-275 Induces Apoptosis in erbB2-Overexpressing Breast Cancer Cells via Down-regulation of erbB3 Expression

(2009) X. Huang et al.   CANCER RESEARCH

The Emerging Role of EpCAM in Cancer and Stem Cell Signaling

(2009) M. Munz et al.   CANCER RESEARCH

Nuclear signalling by tumour-associated antigen EpCAM

(2009) Dorothea Maetzel et al.   NATURE CELL BIOLOGY

The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2

(2008) S.-M. Park et al.   GENES & DEVELOPMENT

ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor

(2008) Jiang Fan et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Generation of Breast Cancer Stem Cells through Epithelial-Mesenchymal Transition

(2008) Anne-Pierre Morel et al.   PLoS One

Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer

(2007) Farhad Vesuna et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS